Skip to main content

Omega Diagnostics First Half Revenue Down Following Reduced Operations - Morningstar


Fairfield Current

Omega Diagnostics First Half Revenue Down Following Reduced Operations
Morningstar
In April, Omega completed a strategic review, resulting in decision to focus on its Visitect CD4 advanced disease teast, as well as its allergy and food intolerance businesses, reducing its cost base significantly. In line with this, Omega sold off its ...
Omega Diagnostics highlights challenges as it reports lossesinsider.co.uk

all 7 news articles »


from india intolerance - Google News https://ift.tt/2Qvpwj8

Comments

Popular posts from this blog